Recombinant human papillomavirus 9 virus-like particle vaccine (6,11,16,18,31,33,45,52,58 L1 protein, shanghai zerun biotechnology)

重组人乳头瘤病毒九价病毒样颗粒疫苗(6、11、16、18、31、33、45、52、58型L1蛋白)(上海泽润生物)

Report date: 2025/10/23 16:20:28

Base Information

Drug NameRecombinant human papillomavirus 9 virus-like particle vaccine (6,11,16,18,31,33,45,52,58 L1 protein, shanghai zerun biotechnology)
Drug Alias Name九价HPV疫苗重组人乳头瘤病毒九价病毒样颗粒疫苗（毕赤酵母）重组人乳头瘤病毒九价疫苗重组人乳头瘤病毒九价病毒样颗粒疫苗（6、11、16、18、31、33、45、52、58型L1蛋白）（毕赤酵母）(沃森生物)
ClassificationVaccines > Biological material > Viral vaccineVaccines > Application > Prophylactic vaccineVaccines > Vaccine type > Multivalent vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsPenile NeoplasmsVaginal NeoplasmsUterine Cervical Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Zerun Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Bovax Biotechnology Co LtdShanghai Zerun Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsPenile NeoplasmsAnus NeoplasmsPapillomavirus Infections +[4] 
Inactive IndicationsVaginal NeoplasmsUterine Cervical Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A